Medical Cardioversion

Several anti-arrhythmic drugs can be used to convert atrial fibrillation into sinus rhythm. Flecainide, sotalol, and amiodarone are available in Australia. If this procedure is selected, no anaesthesia or sedation is necessary. The injection is usually (depending on the drug chosen) given over a period of ten minutes to one hour.

During this time the ECG is monitored continuously and may be recorded from time to time. Usually the arrhythmia will terminate within minutes or at most one to two hours after the injection. The ECG is often monitored for some minutes to hours after the drug has been administered to be sure that any abnormal rhythm, which may emerge, may be quickly detected and treated. When the situation is stable the patient is allowed to go home. If the atrial fibrillation has not been converted to normal sinus rhythm, another treatment strategy will be discussed with the patient. Cardioversion with medicines should follow the same rules as for electrical cardioversion.

It is possible to convert early onset atrial fibrillation by taking anti-arrhythmic medicines by mouth. However, at normal doses, this may take several days or weeks to occur. Amiodarone is usually the most effective agent, although sotalol and other drugs such as flecainide and propafenone may be effective in some patients. Administration of a higher than normal dose of anti-arrhythmic medication is usually more successful but this must be done initially in hospital to test the effect and safety of the technique.

Acknowledgements: Professor A John Camm EP, Dr Matthew Fay GP, Mrs Jayne Mudd, Arrhythmia Nurse Specialist

AF-A Australia Medical Advisory Committee: Dr Michael Davis  Professor Ben Freedman  Dr Gerry Kaye
Founder & CEO: Mrs Trudie Lobban MBE  Deputy CEO: Mrs Jo Jerrome
© AF Association Published January 2009, Reviewed July 2013, Planned Review Date July 2018
This factsheet has been adapted for AF Association Australia with kind permission from the AF Association www.afa.org.uk

Please remember that this publication provides general guidelines only. Individuals should always discuss their condition with a healthcare professional. If you would like further information or would like to provide feedback please contact AF-A.